Authors: Tosi, Anna; Cappellesso, Rocco; Dei Tos, Angelo Paolo; Rossi, Valentina; Aliberti, Camillo; Pigozzo, Jacopo; Fabozzi, Alessio; Sbaraglia, Marta; Blandamura, Stella; Del Bianco, Paola; Chiarion-Sileni, Vanna; Rosato, Antonio
Online: https://doi.org/10.1186/s13046-021-01947-1
Issue: J Exp Clin Cancer Res. 2021 May 4;40(1):154.
Abstract
Uveal melanoma (UM) represents the most common primary intra-ocular malignancy in adults. Up to 50% of the patients develop distant metastases within 10 years from diagnosis, with the liver as the most common site. Upon metastatization, life expectancy strongly reduces and immune checkpoint inhibitors that prove effective in cutaneous melanoma do not modify clinical outcome. To date, few studies have focused on deciphering the immunomodulatory features of metastatic UM microenvironment, and there are no prognostic models for clinical use. This highlights the urgent need to understand the delicate interplay between tumor and immune cells acting at the site of metastasis.
